Benzinga

Benzinga

Benzinga

miércoles, agosto 19

AbCellera Biologics Inc

ABCLNASDAQ
Trade with Public
Trade with Public
$11.12
-0.08-0.71%
al cierre: Aug 18, 5:00 PM EST
$11.06
-0.0599-0.54%
After hour: 7:58 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

AbCellera Biologics Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbCellera Biologics (ABCL).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$13Upside to Avg. PT+17.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Truist SecuritiesRobyn KamausPT RaiseBuy$12→$30
Aug 6, 2026StifelStephen WilleyPT RaiseBuy$8→$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.
Benzinga Newsdesk

PRO
Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.
Benzinga Newsdesk

PRO
Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11

Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved